#Article: Dynogen IBS treatment has good results in trial (IBS-D)

This looks really promising for us IBS-D sufferers. 71pc response rate vs 25pc placebo... seems pretty effective. Wonder what the mechanics of it are.





http://www.bizjournals.com/boston/stories/2007/12/17/daily1.html

Dynogen IBS treatment has good results in trial
Boston Business Journal


Anyone with stomach problems will want to read this story.

A new treatment for patients who suffer from irritable bowel syndrome with diarrhea has generated promising results in a mid-stage human clinical trial.

The drug, developed by Waltham, Mass.-based Dynogen Pharmaceuticals Inc., generated a statistically significant response rate involving 87 women at multiple sites in the United States and Canada.

Over the eight-week trial, a one milligram-dose of DDP225 achieved a 71 percent response rate in helping give patients relief of IBS pain and discomfort, versus a 25 percent response rate for placebo.

The drug will likely advance to Phase III clinical trials, the last phase of testing to be completed before a drug can be submitted for federal regulatory approval.

Dynogen's positive data is good news for people who suffer from irritable bowel syndrome, which affects about 27 million people in the United States alone.

The condition involves abdominal pain and discomfort as well as diarrhea.

This should be very interesting to follow up on...I was wondering when they'd come up with a neurotransmitter reuptake inhibitor designed specifically for IBS!

They've found that people with IBS tend to have decreased levels of available norepinephrine in the intestine, which is required for regular motility. By administering a noradrenaline (or norepinephrine)-reuptake inhibitor, more of that neurotransmitter will be available and, hopefully, that would help in regulating the contractility of the gut. It's kind of the same idea behind the selective serotonin reuptake inhibitors (SSRIs) like Prozac, Zoloft, etc. but with a different class of neurotransmitters.